|[June 26, 2014]
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
MIRAMAR BEACH, Fla. --(Business Wire)--
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable,
sustained-release technology poised to vastly improve patients' use of
Naltrexone, new research into the drug's potential could soon
dramatically expand the drug's market and usage.
Naltrexone has been approved by the FDA for use in combatting alcohol
and heroin addiction by fine-tuning the brain's chemical rewards system
to help reduce cravings. But new research into the drug's properties has
revealed promising applications for the treatment of autoimmune diseases
and chronic pain.
Last month, researchers at Pennsylvania State University, Hershey,
showed that the opioid-receptor antagonist modifies established disease
in a mouse model of relapsing-remitting multiple sclerosis. Preliminary
studies have also suggested that Naltrexone may be an effective
treatment for patients with fibromyalgia, Crohn's Disease, lupus,
rheumatoid arthritis and other illnesses, as well.
As the usefulness of the drug is carefully reexamined in the treatment
of a number of diseases, RBCC is working to make Naltrexone easier to
administer effectively than ever before. The company formed a joint
venture with TheraKine, Ltd., to develop a sustained-release technology
poised to vastly improve patients' use of Naltrexone. Phase I of the
joint venture's research established excellent compatibility between the
drug and TheraKine's hydrophobic injection matrix, as well as a highly
promising release profile. Phase II focused on micronization of the
technology as well as extension of its sustained release time.
This summer, RBCC will focus on demonstrating the new technology's
readiness for market.
RBCC's biotech division, Rainbow BioSciences, is working with partners
such as TheraKine to capitalize on the incredible growth of the global
drug elivery market by delivering new medical and research technology
innovations in order to compete alongside companies such as Bristol
Myers Squibb Co. (BMY),
Biogen Idec Inc. (BIIB),
Abbott Laboratories (ABT)
and Valeant Pharmaceuticals International (VRX).
For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit www.RainbowBioSciences.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To TMCnet.com's Homepage ]